Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an announcement.
Racura Oncology Limited has disclosed a change in the holdings of director Daniel Tillett, who has increased his stake in the company through the exercise of share options. Tillett converted 200,000 options at an exercise price of $1.25 into fully paid ordinary shares for a total consideration of $250,000, lifting his direct shareholding to just over 19 million shares.
Following this transaction, Tillett’s remaining option holdings have decreased accordingly, while his equity exposure to Racura Oncology has risen. The move signals continued financial commitment from a key board member and may be interpreted by investors as a sign of confidence in the company’s prospects and long-term value creation in the oncology space.
More about Race Oncology Ltd.
Racura Oncology Limited is an Australian-listed biotechnology company focused on oncology. The company develops and commercialises cancer therapies, aiming to advance innovative treatments for patients and create value for shareholders in the healthcare and life sciences sector.
Average Trading Volume: 198,668
Technical Sentiment Signal: Buy
Current Market Cap: A$484.7M
See more insights into RAC stock on TipRanks’ Stock Analysis page.